Idiopathic hypersomnia is a 24-hour disorder
Abstract
Idiopathic hypersomnia is a heterogeneous disorder with daytime and nighttime symptoms that have a profound 24-hour effect on individuals' well-being. Daytime signs and symptoms include excessive daytime sleepiness, unrefreshing naps, autonomic dysfunction, fatigue, and brain fog; nighttime signs and symptoms include long sleep, and sleep inertia. Symptom overlap between idiopathic hypersomnia and narcolepsy type 2 and the varied disease course of idiopathic hypersomnia present challenges in diagnosis. Furthermore, the diagnostic criteria for idiopathic hypersomnia are inadequate in their current form, and their use can lead to misdiagnosis and suboptimal treatment. The unclear pathophysiology of idiopathic hypersomnia and the absence of reliable biomarkers necessitate careful use of a variety of tests to make an accurate diagnosis. The Idiopathic Hypersomnia Severity Scale captures symptoms that distinguish idiopathic hypersomnia from narcolepsy, but this scale requires further evaluation in real-world populations and should be used with objective measures of sleep parameters and other validated instruments to accurately capture the full range of symptoms over a 24-hour period. This review describes a holistic view of the symptoms and impact of idiopathic hypersomnia, and frames diagnostic challenges and treatment considerations within the context of this view. Expert clinical opinion that aims to improve the diagnostic accuracy and treatment of idiopathic hypersomnia is…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.